2018

• Non-Coding RNAs in Cutaneous Melanoma Development, Progression and Dissemination. Virginie Vignard and Delphine Fradin. OBM Genetics 2018, Volume 2, Issue 2 doi:10.21926/obm.genet.1802020.

December 2018

• miR-370-3p Is a Therapeutic Tool in Anti-glioblastoma Therapy but Is Not an Intratumoral or Cell-free Circulating Biomarker. Nadaradjane A, Briand J, Bougras-Cartron G, Disdero V, Vallette FM, Frenel JS, Cartron PF. Mol Ther Nucleic Acids. 2018 Dec 7;13:642-650. doi: 10.1016/j.omtn.2018.09.007.

November 2018

• Loss of miR-198 and -206 during primary tumor progression enables metastatic dissemination in human osteosarcoma. Georges S, Calleja LR, Jacques C, Lavaud M, Moukengue B, Lecanda F, Quillard T, Gabriel MT, Cartron PF, Baud'huin M, Lamoureux F, Heymann D, Ory B. Oncotarget. 2018 Nov 6;9(87):35726-35741. doi: 10.18632/oncotarget.26284. eCollection 2018 Nov 6.
• Interplay between transcription regulators RUNX1 and  FUBP1 activates an enhancer of the oncogene c-KIT and amplifies cell proliferation. Debaize L, Jakobczyk H, Avner S, Gaudichon J, Rio AG, Sérandour AA, Dorsheimer  L, Chalmel F, Carroll JS, Zörnig M, Rieger MA, Delalande O, Salbert G, Galibert  MD, Gandemer V, Troadec MB.        Nucleic Acids Res. 2018 Nov 30;46(21):11214-11228.
• Sensitive tumour detection and classification using plasma cell-free DNA methylomes. Shen SY, Singhania R, Fehringer G, Chakravarthy A, Roehrl MHA, Chadwick D, Zuzarte PC, Borgida A, Wang TT, Li T, Kis O, Zhao Z, Spreafico A, Medina TDS, Wang Y, Roulois D, Ettayebi I, Chen Z, Chow S, Murphy T, Arruda A, O'Kane GM, Liu J, Mansour M, McPherson JD, O'Brien C, Leighl N, Bedard PL, Fleshner N, Liu G, Minden MD, Gallinger S, Goldenberg A, Pugh TJ, Hoffman MM, Bratman SV, Hung RJ, De Carvalho DD. Nature. 2018 Nov;563(7732):579-583. doi: 10.1038/s41586-018-0703-0.

September 2018

• TRPS1 regulates oestrogen receptor binding and histone acetylation at enhancers. Serandour AA, Mohammed H, Miremadi A, Mulder KW, Carroll JS. Oncogene. 2018  Sep;37(39):5281-5291. doi: 10.1038/s41388-018-0312-2.

August 2018

• Resistance to complement activation, cell membrane hypersialylation and relapses in chronic lymphocytic leukemia patients treated with rituximab and chemotherapy. Bordron A, Bagacean C, Mohr A, Tempescul A, Bendaoud B, Deshayes S, Dalbies F, Buors C, Saad H, Berthou C, Pers JO, Renaudineau Y. Oncotarget. 2018 Aug 3;9(60):31590-31605. doi: 10.18632/oncotarget.25657. eCollection 2018 Aug 3.

July 2018

• Epigenetic metalloenzymes. Blanquart C, Linot C, Cartron PF, Tomaselli D, Mai A, Bertrand P. Curr Med Chem. 2018 Jul 5. doi: 10.2174/0929867325666180706105903.

June 2018

• Assessment of new HDAC inhibitors for immunotherapy of malignant pleural mesothelioma.Bensaid D, Blondy T, Deshayes S, Dehame V, Bertrand P, Grégoire M, Errami M, Blanquart C. Clin Epigenetics. 2018 Jun 18;10:79. doi: 10.1186/s13148-018-0517-9. eCollection 2018.

February 2018

• PD-L1 expression is regulated by both DNA methylation and NF-kB during EMT signaling in non-small cell lung carcinoma.
  Asgarova A, Asgarov K, Godet Y, Peixoto P, Nadaradjane A, Boyer-Guittaut M, Galaine J, Guenat D, Mougey V, Perrard J, Pallandre JR, Bouard A, Balland J, Tirole C, Adotevi O, Hendrick E, Herfs M, Cartron PF, Borg C, Hervouet E.
  Oncoimmunology. 2018 Feb 1;7(5):e1423170. doi: 10.1080/2162402X.2017.1423170. eCollection 2018.

• Specific or not specific recruitment of DNMTs for DNA methylation, an epigenetic dilemma.
  Hervouet E, Peixoto P, Delage-Mourroux R, Boyer-Guittaut M, Cartron PF.
  Clin Epigenetics. 2018 Feb 9;10:17. doi: 10.1186/s13148-018-0450-y. eCollection 2018. Review.